[
  {
    "ts": "2025-11-06T07:00:00+00:00",
    "headline": "Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe",
    "summary": "INCHEON, Korea, November 06, 2025--Samsung Bioepis has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, in Europe.",
    "url": "https://finance.yahoo.com/news/samsung-bioepis-reaches-settlement-agreement-070000640.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "fa3a3d6e-5d39-3908-99eb-8e2569a0ce24",
      "content": {
        "id": "fa3a3d6e-5d39-3908-99eb-8e2569a0ce24",
        "contentType": "STORY",
        "title": "Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe",
        "description": "",
        "summary": "INCHEON, Korea, November 06, 2025--Samsung Bioepis has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, in Europe.",
        "pubDate": "2025-11-06T07:00:00Z",
        "displayTime": "2025-11-06T07:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/7a49bdfefeb7a07f0664d74a47feb882",
          "originalWidth": 1270,
          "originalHeight": 458,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5JClszrsFXRA9E1uoDDGQQ--~B/aD00NTg7dz0xMjcwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7a49bdfefeb7a07f0664d74a47feb882.cf.webp",
              "width": 1270,
              "height": 458,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vD0.OjrecitfjTPx2yujTA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7a49bdfefeb7a07f0664d74a47feb882.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/samsung-bioepis-reaches-settlement-agreement-070000640.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/samsung-bioepis-reaches-settlement-agreement-070000640.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:51:28+00:00",
    "headline": "AstraZeneca CEO bullish on record revenue numbers and US growth",
    "summary": "AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.",
    "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "0afbe5d4-9f21-3316-ab2a-9a45fb5e7450",
      "content": {
        "id": "0afbe5d4-9f21-3316-ab2a-9a45fb5e7450",
        "contentType": "VIDEO",
        "title": "AstraZeneca CEO bullish on record revenue numbers and US growth",
        "description": "<p>AstraZeneca's (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/AZN\">AZN</a>, <a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/AZN.L\">AZN.L</a>, <a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/AZN.ST\">AZN.ST</a>) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/JNJ\">JNJ</a>), Merck (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/MRK\">MRK</a>) and Pfizer (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/PFE\">PFE</a>). For more live coverage of the markets, watch the full episode of <em>Market Sunrise</em> and visit<a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/\"> Yahoo Finance</a>.</p>",
        "summary": "AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.",
        "pubDate": "2025-11-06T12:51:28Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab",
          "originalWidth": 4787,
          "originalHeight": 2695,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YZigCM3MtAH584LADKiEmA--~B/aD0yNjk1O3c9NDc4NzthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab.cf.webp",
              "width": 4787,
              "height": 2695,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Lb3cKjiVc_C_ZhL48TzyZw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:30:00+00:00",
    "headline": "FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA® (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults. The approval – the first under J&J leadership following its acquisition of Intra-Cellular Therapies, Inc. – provides patients with a safe and effective new treatment option that can enable a path to remission. CAPLYTA® makes it easy to start and stay on treatmen",
    "url": "https://finance.yahoo.com/news/fda-approval-caplyta-lumateperone-potential-123000377.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "4799bc13-2f23-3f80-8a0b-c6b93a1f80d5",
      "content": {
        "id": "4799bc13-2f23-3f80-8a0b-c6b93a1f80d5",
        "contentType": "STORY",
        "title": "FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder",
        "description": "",
        "summary": "Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA® (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults. The approval – the first under J&J leadership following its acquisition of Intra-Cellular Therapies, Inc. – provides patients with a safe and effective new treatment option that can enable a path to remission. CAPLYTA® makes it easy to start and stay on treatmen",
        "pubDate": "2025-11-06T12:30:00Z",
        "displayTime": "2025-11-06T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/2bca77195bc78302701e20c6f02a5fbd",
          "originalWidth": 400,
          "originalHeight": 38,
          "caption": "Johnson & Johnson",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FZ85NytkUmTKmOiWzw_W_g--~B/aD0zODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2bca77195bc78302701e20c6f02a5fbd.cf.webp",
              "width": 400,
              "height": 38,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ef4HGBIVATVjjNCFfw3E7Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/2bca77195bc78302701e20c6f02a5fbd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-approval-caplyta-lumateperone-potential-123000377.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approval-caplyta-lumateperone-potential-123000377.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ITCI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T15:23:00+00:00",
    "headline": "Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players",
    "summary": "The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The \"Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering. Co",
    "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c84240ee-2762-3b00-8d10-c69c01b0f6f9",
      "content": {
        "id": "c84240ee-2762-3b00-8d10-c69c01b0f6f9",
        "contentType": "STORY",
        "title": "Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players",
        "description": "",
        "summary": "The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The \"Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering. Co",
        "pubDate": "2025-11-06T15:23:00Z",
        "displayTime": "2025-11-06T15:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAYN.DE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CYTK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "4502.T"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T16:39:36+00:00",
    "headline": "AstraZeneca to pour $50bn into US ahead of New York listing as UK investment plans stall",
    "summary": "The company has paused some UK investment plans, citing declining government support for pharmaceutical innovation.",
    "url": "https://uk.finance.yahoo.com/news/astrazeneca-us-investment-new-york-listing-163936444.html",
    "source": "Yahoo Finance UK",
    "provider": "yfinance",
    "raw": {
      "id": "9aba44ce-6377-42df-af30-a766c5758c13",
      "content": {
        "id": "9aba44ce-6377-42df-af30-a766c5758c13",
        "contentType": "STORY",
        "title": "AstraZeneca to pour $50bn into US ahead of New York listing as UK investment plans stall",
        "description": "",
        "summary": "The company has paused some UK investment plans, citing declining government support for pharmaceutical innovation.",
        "pubDate": "2025-11-06T16:39:36Z",
        "displayTime": "2025-11-06T16:40:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/fc55e1c0-bb2b-11f0-acfd-85500221de7f",
          "originalWidth": 4500,
          "originalHeight": 3000,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/snkOq7ZRGEMlw358l6Qbmw--~B/aD0zMDAwO3c9NDUwMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/fc55e1c0-bb2b-11f0-acfd-85500221de7f.cf.webp",
              "width": 4500,
              "height": 3000,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qv4mtGYShx_XW.HScYaSoA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/fc55e1c0-bb2b-11f0-acfd-85500221de7f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance UK",
          "url": "http://uk.finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/astrazeneca-us-investment-new-york-listing-163936444.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/astrazeneca-us-investment-new-york-listing-163936444.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T11:03:00+00:00",
    "headline": "J&J brain drug acquired in $14.6B buyout cleared for broader use",
    "summary": "Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s key to achieving the $5 billion in annualized sales the company expects.",
    "url": "https://www.biopharmadive.com/news/johnson-johnson-caplyta-fda-major-depressive-disorder-/804846/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "63afa494-a2ce-3772-93c5-04362c59f7de",
      "content": {
        "id": "63afa494-a2ce-3772-93c5-04362c59f7de",
        "contentType": "STORY",
        "title": "J&J brain drug acquired in $14.6B buyout cleared for broader use",
        "description": "",
        "summary": "Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s key to achieving the $5 billion in annualized sales the company expects.",
        "pubDate": "2025-11-06T11:03:00Z",
        "displayTime": "2025-11-06T11:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/2dbfb3f6cd01d8219f3b5bd6caf25513",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "Johnson & Johnson's pharmaceutical office in Madrid, Spain. The company is investing $2 billion to expand its manufacturing capacity at Fujifilm Biotechnologies' facility in Holly Springs, North Carolina.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kLzx91cSWTinolPxCr_H5Q--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/2dbfb3f6cd01d8219f3b5bd6caf25513.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/P_stM0vQsDmV0T6XfqQb1g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/2dbfb3f6cd01d8219f3b5bd6caf25513.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/johnson-johnson-caplyta-fda-major-depressive-disorder-/804846/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-brain-drug-acquired-110300011.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T17:34:58+00:00",
    "headline": "J&J’s Caplyta wins MDD approval to extend revenue horizon",
    "summary": "Caplyta’s MDD label extension marks the first approval since J&J acquired the drug in a $14.6bn buyout.",
    "url": "https://www.pharmaceutical-technology.com/news/jjs-caplyta-wins-mdd-approval-to-extend-revenue-horizon/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "a9feaaef-7070-3926-b1e4-2dab8f00641b",
      "content": {
        "id": "a9feaaef-7070-3926-b1e4-2dab8f00641b",
        "contentType": "STORY",
        "title": "J&J’s Caplyta wins MDD approval to extend revenue horizon",
        "description": "",
        "summary": "Caplyta’s MDD label extension marks the first approval since J&J acquired the drug in a $14.6bn buyout.",
        "pubDate": "2025-11-06T17:34:58Z",
        "displayTime": "2025-11-06T17:34:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/fbb840273f3003c1f4b4a91f869d6085",
          "originalWidth": 2560,
          "originalHeight": 1920,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tCX4Gwbh46vKmmVHM7efeg--~B/aD0xOTIwO3c9MjU2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/pharmaceutical_technology_376/fbb840273f3003c1f4b4a91f869d6085.cf.webp",
              "width": 2560,
              "height": 1920,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ak51yjCn_dpGM04yhq0_9Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/fbb840273f3003c1f4b4a91f869d6085.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/jjs-caplyta-wins-mdd-approval-to-extend-revenue-horizon/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-caplyta-wins-mdd-173458310.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ITCI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T17:31:39+00:00",
    "headline": "Texas Attorney General Files Motion to Stop Kenvue From Paying November Dividends",
    "summary": "Attorney General Ken Paxton filed a motion in a Texas District court on Wednesday to prevent Kenvue",
    "url": "https://finance.yahoo.com/news/texas-attorney-general-files-motion-173139995.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "f22f639e-06da-32b2-9174-48d8f35e05f0",
      "content": {
        "id": "f22f639e-06da-32b2-9174-48d8f35e05f0",
        "contentType": "STORY",
        "title": "Texas Attorney General Files Motion to Stop Kenvue From Paying November Dividends",
        "description": "",
        "summary": "Attorney General Ken Paxton filed a motion in a Texas District court on Wednesday to prevent Kenvue",
        "pubDate": "2025-11-06T17:31:39Z",
        "displayTime": "2025-11-06T17:31:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/texas-attorney-general-files-motion-173139995.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/texas-attorney-general-files-motion-173139995.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T21:18:33+00:00",
    "headline": "How Recent Developments Are Shaping the Johnson & Johnson Investment Story",
    "summary": "Johnson & Johnson's stock price target has seen a slight increase, with the Fair Value Estimate rising from $198.03 to $199.56 following recent analyst updates. This adjustment reflects the company's strong operational performance, a positive outlook on business portfolio changes, and encouraging signals from its innovative medicine segment. Stay tuned to discover how you can continue tracking the evolving narrative around Johnson & Johnson's shares as the story develops. Analyst Price...",
    "url": "https://finance.yahoo.com/news/recent-developments-shaping-johnson-johnson-211833189.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "f7fc541e-0d25-394b-8472-f70475601528",
      "content": {
        "id": "f7fc541e-0d25-394b-8472-f70475601528",
        "contentType": "STORY",
        "title": "How Recent Developments Are Shaping the Johnson & Johnson Investment Story",
        "description": "",
        "summary": "Johnson & Johnson's stock price target has seen a slight increase, with the Fair Value Estimate rising from $198.03 to $199.56 following recent analyst updates. This adjustment reflects the company's strong operational performance, a positive outlook on business portfolio changes, and encouraging signals from its innovative medicine segment. Stay tuned to discover how you can continue tracking the evolving narrative around Johnson & Johnson's shares as the story develops. Analyst Price...",
        "pubDate": "2025-11-06T21:18:33Z",
        "displayTime": "2025-11-06T21:18:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/recent-developments-shaping-johnson-johnson-211833189.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/recent-developments-shaping-johnson-johnson-211833189.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T22:06:00+00:00",
    "headline": "DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma",
    "summary": "Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).1 DARZALEX FASPRO® is the first and only approved treatment for HR-SMM, enabling earlier intervention before the disease progresses to active multiple myeloma.",
    "url": "https://finance.yahoo.com/news/darzalex-faspro-first-only-treatment-220600216.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "1dfd9dfc-5dd3-3a31-94bd-8c2fdc6e25f6",
      "content": {
        "id": "1dfd9dfc-5dd3-3a31-94bd-8c2fdc6e25f6",
        "contentType": "STORY",
        "title": "DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).1 DARZALEX FASPRO® is the first and only approved treatment for HR-SMM, enabling earlier intervention before the disease progresses to active multiple myeloma.",
        "pubDate": "2025-11-06T22:06:00Z",
        "displayTime": "2025-11-06T22:06:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721",
          "originalWidth": 400,
          "originalHeight": 38,
          "caption": "Johnson & Johnson (PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GXCxbsFDDz3fFTI03HwuBw--~B/aD0zODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721.cf.webp",
              "width": 400,
              "height": 38,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qhQKh0p3toIAfsx9SijYTA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/darzalex-faspro-first-only-treatment-220600216.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/darzalex-faspro-first-only-treatment-220600216.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]